Under the Paperwork Reduction Act of 1995, no persons are required to respon

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number			10800067	
	Filing Date		2004-03-12	
First Named Inventor Jurkie		Jurki	ewicz et al.	
	Art Unit		2122	
	Examiner Name	BOU	TSIKARIS, LEONIDAS	
	Attorney Docket Number		RSW920030262US1	

	U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6917929	B2	2005-07-12	Teloh et al.				
	2	7013331	B2	2006-03-14	Das				
	3	6618805	B1	2003-09-09	Kampe				
If you wis	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.		Add		
			U.S.P	ATENT APPL	ICATION PUBLICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document		nt Passag	Lines where les or Relevan	
	1	20040205162	A1	2004-10-14	Parikh				
	2	20050055595	A1	2005-03-10	Frazer et al.				
	3	20040010786	A1	2004-01-15	Cool et al.				
							Add		

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10800067
Filing Date		2004-03-12
First Named Inventor Jurki		ewicz et al.
Art Unit		2122
Examiner Name BOU		TSIKARIS, LEONIDAS
Attament Dealest Monther		DCM0300303031104

Examiner Initial*	Cite No	Forei	gn Document ber <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee of Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	Ts
	1								
If you wish	h to a	dd add	itional Foreign	Patent Documen	t citation	information p	lease click the Add bu	itton Add	
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	Examiner Cite (nitials* No lobisher, city ander country where publisher.				Ţŝ				
	1								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

See Kind Codes of USPTO Patent Documents at sweru(SPTO\_GOV) or MPEP 901.04. Enter office that issued the document, by the how-left or (WIPO) Standard ST3.) For Lapraesee patent documents, the ancidation of the year of the region or preceded the service of the expense or the patent document. If Anni of Cocument by the appropriate symbols as andicated on the document under WIPO Standard ST.16 if possible. Speciation is to place a check mark here if English supraugate Precision is adstanced.

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10800067	
Filing Date		2004-03-12	
First Named Inventor	Jurki	ewicz et al.	
Art Unit		2122	
Examiner Name BOU		TSIKARIS, LEONIDAS	
Attorney Docket Number		RSW920030262US1	

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) the control of the contro

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gerald H. Glanzman/	Date (YYYY-MM-DD)	2006-10-10				
Name/Print	Geraid H. Glanzman	Registration Number	25035				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GAD 47 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.